SCHEMBL1166720

SCHEMBL1166720

CC(=O)c1ccc(Cn2cc(NC(=O)c3nc(C)oc3-c3cccc(C(F)(F)F)c3)cn2)o1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR2 O43614 10/20 0.63
HCRTR1 O43613 5/20 0.63
ALDH1A1 P00352 4/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
CYP1A2 P05177 1/20 0.55
CYP2D6 P10635 1/20 0.55
MAPT P10636 1/20 0.55
CYP2C9 P11712 1/20 0.55
CYP2C19 P33261 1/20 0.55
FPR2 P25090 2/20 0.51
SCD5 Q86SK9 2/20 0.44
LMNA P02545 2/20 0.44
PKM P14618 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
SCD O00767 1/20 0.42
HTT P42858 2/20 0.42
KDM4E B2RXH2 1/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1167173 0.90 HCRTR2 (0.66) HCRTR2HCRTR1ALDH1A1MEN1KMT2A
SCHEMBL1167151 0.90 HCRTR2 (0.78) HCRTR2HCRTR1
SCHEMBL1166400 0.89 HCRTR2 (0.67) HCRTR2HCRTR1ALDH1A1SMN1; SMN2SCD5
SCHEMBL1166303 0.89 HCRTR2 (0.63) HCRTR2HCRTR1ALDH1A1SMN1; SMN2MEN1
SCHEMBL1166921 0.88 HCRTR2 (0.66) HCRTR2HCRTR1ALDH1A1SMN1; SMN2MEN1
SCHEMBL1166992 0.88 HCRTR2 (0.64) HCRTR2HCRTR1ALDH1A1SMN1; SMN2FPR2
SCHEMBL1165916 0.88 HCRTR2 (0.80) HCRTR2HCRTR1ALDH1A1SMN1; SMN2MEN1
SCHEMBL1167000 0.87 HCRTR2 (0.64) HCRTR2HCRTR1ALDH1A1MEN1KMT2A
SCHEMBL1167751 0.85 HCRTR2 (0.66) HCRTR2HCRTR1ALDH1A1SMN1; SMN2MEN1
SCHEMBL1166991 0.85 FPR2 (0.54) HCRTR2HCRTR1ALDH1A1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110034516-A1 AMINOPYRAZOLE DERIVATIVES ACTELION (CH) 2011-02-10 US claimed
US-20110034516-A1 AMINOPYRAZOLE DERIVATIVES ACTELION (CH) 2011-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034516-A1 AMINOPYRAZOLE DERIVATIVES CYP3A43, CYP1A2, CYP3A5 HCRTR2 2700/4885HCRTR1 2862/4885ALDH1A1 96/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.